Immunocore’s (IMCR) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Immunocore (NASDAQ:IMCR) in a research note issued to investors on Friday, Benzinga reports. They currently have a $100.00 price objective on the stock.

Several other equities research analysts also recently weighed in on the stock. SVB Leerink initiated coverage on shares of Immunocore in a research report on Monday, April 29th. They set an outperform rating and a $74.00 price target for the company. Mizuho cut their target price on shares of Immunocore from $90.00 to $88.00 and set a buy rating for the company in a research report on Monday, May 13th. Needham & Company LLC restated a buy rating and set a $81.00 target price on shares of Immunocore in a research note on Friday. Canaccord Genuity Group lifted their target price on shares of Immunocore from $63.00 to $67.00 and gave the company a hold rating in a research note on Thursday, May 9th. Finally, Leerink Partnrs restated an outperform rating on shares of Immunocore in a research note on Monday, April 29th. Two research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of Moderate Buy and a consensus price target of $81.85.

Immunocore Trading Down 4.0 %

IMCR traded down $1.93 during midday trading on Friday, reaching $46.05. 5,140,250 shares of the company were exchanged, compared to its average volume of 656,852. The company has a debt-to-equity ratio of 1.22, a quick ratio of 5.94 and a current ratio of 5.96. The company’s fifty day moving average price is $58.46 and its 200 day moving average price is $61.88. Immunocore has a one year low of $41.01 and a one year high of $76.98.

Immunocore (NASDAQ:IMCR) last released its earnings results on Wednesday, May 8th. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.12). Immunocore had a negative net margin of 22.60% and a negative return on equity of 16.54%. The firm had revenue of $70.30 million during the quarter, compared to the consensus estimate of $70.72 million. During the same period in the prior year, the company earned ($0.35) EPS. The firm’s revenue was up 27.6% compared to the same quarter last year. Equities research analysts forecast that Immunocore will post -1.88 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of IMCR. Bellevue Group AG raised its stake in shares of Immunocore by 4,817.1% in the fourth quarter. Bellevue Group AG now owns 976,054 shares of the company’s stock valued at $66,684,000 after purchasing an additional 956,204 shares in the last quarter. Braidwell LP grew its holdings in shares of Immunocore by 93.8% during the third quarter. Braidwell LP now owns 906,973 shares of the company’s stock worth $47,072,000 after purchasing an additional 438,946 shares during the last quarter. Wellington Management Group LLP boosted its holdings in Immunocore by 10.2% in the fourth quarter. Wellington Management Group LLP now owns 4,312,611 shares of the company’s stock valued at $294,638,000 after acquiring an additional 399,201 shares during the last quarter. First Turn Management LLC bought a new position in Immunocore in the fourth quarter valued at about $23,439,000. Finally, Polar Capital Holdings Plc boosted its holdings in Immunocore by 490.5% in the third quarter. Polar Capital Holdings Plc now owns 250,000 shares of the company’s stock valued at $12,975,000 after acquiring an additional 207,664 shares during the last quarter. 84.50% of the stock is currently owned by institutional investors and hedge funds.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.